Posted by Michael Wonder on 14 Aug 2023
US FDA approves first therapeutic indication for Revance’s Daxxify (daxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia
14 August 2023 - Approval expands the Daxxify label to include efficacy data over the 52 week ASPEN repeat dose clinical study.
Revance Therapeutics today announced that the US FDA has approved the first therapeutic indication for Daxxify (daxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults.
